Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
| 适应症 | Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 |
|---|---|
| 分期 | 1/2期 |
| 申办方 | National Cancer Institute (NCI) |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 22 人 |
| 干预（药物） | Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Osimertinib, Positron Emission Tomography |
| 开始日期 | 2020年3月16日 |
| 完成日期 | 2024年6月12日 |
| 结果公布日 | 2025年6月19日 |
摘要
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recommended Phase II Dose (RP2D)
| Phase 1b Cohorts | 800 milligrams |
|---|---|
| Phase 1b Cohorts | 80 milligrams |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)